Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...

AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...

Pathmaker's MyoRegulator is designed to ease hyperexcitability and delivers an electrical current to the spinal cord and ...

Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...

Columnist Dagmar Munn says she has often felt out of place in the ALS community because of the slower pace of her disease progression.

ALS impacts tens of thousands of people across the United States, and hundreds in Arizona. There's research being done in the Valley that can hopefully help contribute to ending ALS.

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of ...

ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...